Home Healthcare Immuno Oncology IO Market
immuno oncology IO market

Immuno Oncology (IO) Market Share, Size, Trends, Industry Analysis Report By Treatment Approaches; By Novel Targets (IDO1i, LAG-3 CPI, oncolytic virus, STING agonist, TLR agonist, HDACi, TIL, VEGFi, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, A2AR antagonist/CD73i); By Tumor Type; By Region, Segment Forecast, 2022 - 2029

  • Published Date: Jan 2022
  • Pages: 118
  • Format: PDF
  • Report ID: PM1083
  • Base Year: 2020
  • Historical Data: 2017 - 2020

Report Summary

The global immuno oncology (IO) market size was valued at USD 17.56 billion in 2021 and is expected to grow at a CAGR of 23.4% during the forecast period. Innovative technologies along with increased spending on research & development by key market players for better treatment are some factors driving the global immuno oncology (IO) market growth.

Immuno Oncology Market Size
Know more about this report: request for sample pages

I-O therapies are a new type of cancer therapy that uses the individual’s own immune system to combat illness. The therapy improves the immune system to find and destroy cancer cells by using molecules manufactured within the body or in a lab. A shift in the treatment of conventional chemotherapies to immuno oncology therapies is anticipated to propel the immuno oncology (IO) market growth over the forecast period.

Industry Dynamics

Growth Drivers
The fast discovery of I-O treatments for a variety of cancers has changed the scene of cancer therapy and improved the long-term prospects for many progressed cancer patients, which has increased the demand for immuno oncology (IO). Furthermore, increasing investment by the government and several pharmaceutical companies in research & development for treating cancer is expected to drive the immuno oncology (IO) market over the forecast period. However, huge cost as compared to radiotherapy and chemotherapy along with various challenges in clinical trials is expected to restrain the immuno oncology (IO) industry growth over the forecast period.

Report Segmentation

The global immuno-oncology market is segmented on the basis of treatment approaches, novel targets, tumor type, and region.

By Treatment Approaches

By Novel Targets

By Tumor Types

By Region

  • Monoclonal Antibodies
  • Therapeutic Vaccines
  • Checkpoint Inhibitors
  • Cytokines
  • IDO1i
  • LAG-3 CPI
  • Oncolytic virus
  • STING agonist
  • TLR agonist
  • HDACi
  • TIL
  • VEGFi
  • MEKi
  • TIGIT
  • CPI
  • GITR agonist
  • TGF-b trap
  • A2AR antagonist/CD73i
  • Melanoma
  • Non-Small Cell Lung Cancer
  • Renal Cell Carcinoma
  • Head & Neck Cancer
  • Bladder Cancer
  • Classical Hodgkin’s Lymphoma
  • Merkel Cell Carcinoma
  • Others
  • North America (U.S., Canada, Mexico)
  • Europe (Germany, UK, France, Italy, Spain, Netherlands, Austria)
  • Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia)
  • Latin America (Brazil, Argentina)
  • Middle East & Africa (UAE, Saudi Arabia, South Africa, Israel)

Know more about this report: request for sample pages

Insight by Treatment Approaches

Checkpoint inhibitors held the largest market share in 2021 and are expected to dominate the treatment approaches segment over the forecast period. These inhibitors block checkpoint proteins to connect with their companion proteins which allow T cells to destroy cancer cells. Increasing public awareness along with technology innovation are the key factors driving the segment growth.

Geographic Overview

North America dominated the global (IO) market in 2021 and is expected to maintain its dominance over the forecast period due to the rising geriatric population coupled with developed healthcare infrastructure. Moreover, increasing cancer cases along with the presence of key market players in this region is expected to create lucrative opportunities for the immuno oncology (IO) market to grow.

Asia Pacific region is anticipated to grow at a significant pace over the forecast period due to increasing cancer cases along with the rapidly improving pharmaceutical and healthcare industry. Furthermore, increasing investment from private and government organizations is expected to create lucrative opportunities for immuno oncology (IO) market growth.

Competitive Landscape

Some of the players operating in the global market include Amgen, Inc., AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Incyte, Janssen Biotech, Inc., Merck, Novartis AG, Pfizer, Roche, Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals.

Immuno Oncology (IO) Market Report Scope

Report Attributes

Details

Market size value in 2021

USD 17.56 billion

Revenue forecast in 2029

USD 92.71 billion

CAGR

23.4% from 2022 - 2029

Base year

2021

Historical data

2017 - 2020

Forecast period

2022 - 2029

Quantitative units

Revenue in USD million/billion and CAGR from 2022 to 2029

Segments covered

By Treatment Approaches, By Novel Targets, By Tumor Types, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

Key Companies

Amgen, Inc., AstraZeneca, Bristol Myers Squibb, Celgene Corporation, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc., Incyte, Janssen Biotech, Inc., Merck, Novartis AG, Pfizer, Roche, Sanofi, Spectrum Pharmaceuticals and Takeda Pharmaceuticals.

 

Key Take-Away
Polaris Market Research
Global Immuno Oncology (IO) Market Share, Size Industry Analysis report, 2022 - 2029